Transgene SA (OTCMKTS:TRGNF) Sees Significant Growth in Short Interest

by · The Cerbat Gem

Transgene SA (OTCMKTS:TRGNF – Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,095 shares, an increase of ∞ from the April 30th total of 0 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Transgene Stock Performance

TRGNF stock remained flat at $0.85 during trading on Monday. Transgene has a 12-month low of $0.85 and a 12-month high of $1.08. The firm has a fifty day moving average price of $0.93 and a 200-day moving average price of $0.95.

About Transgene

(Get Free Report)

Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.

The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.

Featured Articles